Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L19IL2, L19TNF, or L19IL2/L19TNF + Pembrolizumab in Advanced Melanoma
NCT06284590Phase 2Recruiting
- Sponsor
- Philogen
- Start
- Jul 2024
- Primary completion
- Jul 2028
- Modality
- Antibody Fragments, Immunomodulatory ADCs, Cytokines & Interferons
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of darleukin, onfekafusp alfa and Nidlegy in melanoma (3 arms), sponsored by Philogen. Primary endpoint: Confirmed Objective Response Rate up to 2 years. Started Jul 2024; status: recruiting.
02
Drugs
darleukinonfekafusp alfaNidlegy
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06284590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06284590.